What is the current stock price of Allogene Therapeutics, Inc. (ALLO)?

As of the latest market data, Allogene Therapeutics, Inc. (ALLO) is trading at $2.72. The stock has seen a loss of -6.53% today.

Does Allogene Therapeutics, Inc. (ALLO) pay a dividend?

Based on current data, Allogene Therapeutics, Inc. does not have a confirmed active dividend policy.

What is the market cap of Allogene Therapeutics, Inc.?

The current market capitalization of Allogene Therapeutics, Inc. (ALLO) is approximately unavailable.

ALLO

Allogene Therapeutics, Inc.·Healthcare

2.72

6.529%(−0.19)

Market Closed

3.18

16.912%(+0.46)

After Hours

Last Updated: — ET

52W L: $0.8652W H: $2.95

ALLO NEWS

globenewswire.com

20h ago

Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026

SOUTH SAN FRANCISCO, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced the Company will host a conference call and webcast to review the interim futility analysis from its pivotal, randomized Phase 2 ALPHA3 trial with cemacabtagene ansegedleucel (cema-cel) in first-line (1L) consolidation large B-cell lymphoma (LBCL) on Monday, April 13, 2026.

defenseworld.net

Mar 17

Short Interest in Allogene Therapeutics, Inc. (NASDAQ:ALLO) Rises By 19.8%

Allogene Therapeutics, Inc. (NASDAQ: ALLO - Get Free Report) saw a significant increase in short interest in the month of February. As of February 27th, there was short interest totaling 23,927,216 shares, an increase of 19.8% from the February 12th total of 19,964,416 shares. Based on an average daily volume of 6,048,498 shares, the short-interest ratio

zacks.com

Mar 13

Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4

ALLO posts a narrower Q4 loss than expected, cuts expenses and advances key CAR-T studies, with cash projected to fund operations into 2028.

seekingalpha.com

Mar 13

Allogene Therapeutics, Inc. (ALLO) Q4 2025 Earnings Call Transcript

globenewswire.com

Mar 12

Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter and full year ended December 31, 2025.

zacks.com

Mar 9

Take the Zacks Approach to Beat the Markets: Starbucks, Amgen, Allogene in Focus

ALLO, SBUX and AMGN highlight how Zacks strategies and portfolio picks are delivering strong gains despite recent market volatility.

Company Profile

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Sector

Healthcare

Industry

Biotechnology

Employees

226

IPO Date

2018-10-11

Beta

0.54

Websitewww.allogene.com↗